##gff-version 3
##sequence-region Q96IZ0 1 340
Q96IZ0	UniProtKB	Chain	1	340	.	.	.	ID=PRO_0000058236;Note=PRKC apoptosis WT1 regulator protein	
Q96IZ0	UniProtKB	Region	145	203	.	.	.	Note=Selective for apoptosis induction in cancer cells (SAC)	
Q96IZ0	UniProtKB	Region	300	340	.	.	.	Note=Leucine-zipper	
Q96IZ0	UniProtKB	Coiled coil	186	206	.	.	.	Ontology_term=ECO:0000255;evidence=ECO:0000255	
Q96IZ0	UniProtKB	Motif	68	72	.	.	.	Note=B30.2/SPRY domain-binding motif;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20561531;Dbxref=PMID:20561531	
Q96IZ0	UniProtKB	Motif	145	161	.	.	.	Note=Nuclear localization signal;Ontology_term=ECO:0000250;evidence=ECO:0000250	
Q96IZ0	UniProtKB	Compositional bias	49	120	.	.	.	Note=Ala-rich	
Q96IZ0	UniProtKB	Modified residue	108	108	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:24275569;Dbxref=PMID:24275569	
Q96IZ0	UniProtKB	Modified residue	163	163	.	.	.	Note=Phosphothreonine%3B by PKA;Ontology_term=ECO:0000250;evidence=ECO:0000250|UniProtKB:Q62627	
Q96IZ0	UniProtKB	Modified residue	231	231	.	.	.	Note=Phosphoserine;Ontology_term=ECO:0000244;evidence=ECO:0000244|PubMed:23186163;Dbxref=PMID:23186163	
Q96IZ0	UniProtKB	Natural variant	42	42	.	.	.	ID=VAR_022465;Note=P->L;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.3;Dbxref=dbSNP:rs8176804	
Q96IZ0	UniProtKB	Natural variant	78	78	.	.	.	ID=VAR_022466;Note=P->R;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|Ref.2,ECO:0000269|Ref.3;Dbxref=dbSNP:rs8176805	
Q96IZ0	UniProtKB	Natural variant	137	137	.	.	.	ID=VAR_022467;Note=G->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.3;Dbxref=dbSNP:rs8176806	
Q96IZ0	UniProtKB	Natural variant	202	202	.	.	.	ID=VAR_022468;Note=E->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|Ref.3;Dbxref=dbSNP:rs8176870	
Q96IZ0	UniProtKB	Mutagenesis	66	66	.	.	.	Note=No loss of interaction with SPSB1%2C SPSB2 and SPSB4. A->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20561531;Dbxref=PMID:20561531	
Q96IZ0	UniProtKB	Mutagenesis	68	68	.	.	.	Note=Increased interaction with SPSB2. Only slightly increased interaction with SPSB4. Increased interaction with SPSB1%2C SPSB2 and SPSB4%3B when associated with A-69. E->D;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20561531;Dbxref=PMID:20561531	
Q96IZ0	UniProtKB	Mutagenesis	69	69	.	.	.	Note=Only slighlty increased interaction with SPSB2. Only slightly increased interaction with SPSB4. Increased interaction with SPSB1%2C SPSB2 and SPSB4%3B when associated with A-68. L->I;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20561531;Dbxref=PMID:20561531	
Q96IZ0	UniProtKB	Mutagenesis	71	71	.	.	.	Note=Loss of interaction with SPSB1%2C SPSB2 and SPSB4. N->A;Ontology_term=ECO:0000269;evidence=ECO:0000269|PubMed:20561531;Dbxref=PMID:20561531	
Q96IZ0	UniProtKB	Mutagenesis	72	72	.	.	.	Note=Loss of interaction with SPSB1-Elongin BC complex and SPSB2 and SPSB4. N->A;Ontology_term=ECO:0000269,ECO:0000269;evidence=ECO:0000269|PubMed:17189197,ECO:0000269|PubMed:20561531;Dbxref=PMID:17189197,PMID:20561531	
Q96IZ0	UniProtKB	Sequence conflict	102	103	.	.	.	Note=AP->PPAR;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q96IZ0	UniProtKB	Sequence conflict	199	199	.	.	.	Note=I->M;Ontology_term=ECO:0000305;evidence=ECO:0000305	
Q96IZ0	UniProtKB	Sequence conflict	281	281	.	.	.	Note=R->T;Ontology_term=ECO:0000305;evidence=ECO:0000305	
